Homobivalent quinazolinimines as novel nanomolar inhibitors of cholinesterases with dirigible selectivity toward butyrylcholinesterase

Journal of Medicinal Chemistry

Volumn 49, Issue 18, 2006, Pages 5411-5413

  Decker, Michael ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALICYCLIC COMPOUND; CARBENE; CHOLINESTERASE INHIBITOR; DIMER; DONEPEZIL; GALANTAMINE; IMINE; MONOMER; NANOPARTICLE; NITROGEN; QUINAZOLINE DERIVATIVE; QUINAZOLINEIMINE DERIVATIVE; RIVASTIGMINE; TACRINE; THIOKETONE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ARTICLE; CHOLINESTERASE INHIBITION; DRUG SELECTIVITY; DRUG SYNTHESIS; MOLECULAR SIZE; STRUCTURE ACTIVITY RELATION;

ACETYLCHOLINESTERASE; BUTYRYLCHOLINESTERASE; CHOLINESTERASE INHIBITORS; DIMERIZATION; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; IMINES; LIGANDS; QUINAZOLINES; STRUCTURE-ACTIVITY RELATIONSHIP; TACRINE;

EID: 33748540091     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm060682m     Document Type: Article

References (20)

1. Johnson, C. N.; Roland, A.; Upton, N. New Symptomatic Strategies in Alzheimer's Disease. Drug Discovery Today: Ther. Strategies 2004, 1, 13-19.
2. De Ferrari, G. V.; Canales, M. A.; Shin, I.; Weiner, L. M.; Silman, I.; Inestrosa, N. C. A Structural Motif of Acetylcholinesterase That Promotes Amyloid Beta-Peptide Fibril Formation. Biochemistry 2001, 40, 10447-10457.
3. Mack, A.; Robitzki, A. The Key Role of Butyrylcholinesterase during Neurogenesis and Neural Disorders: An Antisense-5′-butyrylcholinesterase- DNA Study. Prog. Neurobiol. 2000, 60, 607-628.
4. Giacobini, E. Drugs That Target Cholinesterases. In Cognitive Enhancing Drugs; Buccafusco, J. J., Ed.; Birkhäuser Verlag: Basel, Boston, Berlin, 2004; pp 11-36.
5. Giacobini, E.; Spiegel, R.; Enz, A.; Veroff, A.; Cutler, R. E. Inhibition of Acetyl- and Butyryl-cholinesterase in the Cerebrospinal Fluid of Patients with Alzheimer's Disease by Rivastigmine: Correlation with Cognitive Benefit. J. Neural Transm. 2002, 109, 1053-1065.
6. Messer, W. S. Bivalent Ligands for G Protein-Coupled Receptors. Curr. Pharm. Des. 2004, 10, 2015-2020.
7. Decker, M.; Lehmann, J. Agonistic and Antagonistic Bivalent Ligands of Serotonin and Dopamine Receptors Including Their Transporters. Curr. Top. Med. Chem., in press.
8. Muñoz-Torrero, D.; Camps, P. Dimeric and Hybrid Anti-Alzheimer Drug Candidates. Curr. Med. Chem. 2006, 13, 399-422 and references therein.
9. Carlier, P. R.; Han, Y. F.; Chow, E. S.-H.; Li, C. P.-L.; Wang, H.; Lieu, T. X.; Wong, H. S.; Pang, Y. P. Evaluation of Short Tether Bis-THA AChE Inhibitors. A Further Test of the Dual Binding Site Hypothesis. Bioorg. Med. Chem. 1999, 7, 351-357.
10. Savini, L.; Campiani, G.; Gaeta, A.; Pellerano, C.; Fattorusso, C.; Chiasserini, L.; Fedorko, J. M.; Saxena, A. Novel and Potent Tacrine-Related Hetero- and Homobivalent Ligands for Acetylcholinesterase and Butyrylcholinesterase. Bioorg. Med. Chem. Lett. 2001, 11, 1779-1782.
11. Savini, L.; Gaeta, A.; Fattorusso, C.; Catalanotti, B.; Campiani, G.; Chiasserini, L.; Pellerano, C.; Novellino, E.; McKissic, D.; Saxena, A. Specific Targeting of Acetylcholinesterase and Butyrylcholinesterase Recognition Sites. Rational Design of Novel, Selective, and Highly Potent Cholinesterase Inhibitors. J. Med. Chem. 2003, 46, 1-4.
12. Campiani, G.; Fattorusso, C.; Butini, S.; Gaeta, A.; Agnusdei, M.; Gemma, S.; Persico, M.; Catalanotti, B.; Savini, L.; Nacci, V.; Novellino, E.; Holloway, H. W.; Greig, N. H.; Belinskaya, T.; Fedorko, J. M.; Saxena, A. Development of Molecular Probes for the Identification of Extra Interaction Sites in the Mid-Gorge and Peripheral Sites of Butyrylcholinesterase (BuChE). Rational Design of Novel, Selective, and Highly Potent BuChE Inhibitors. J. Med. Chem. 2005, 48, 1919-1929.
13. Decker, M. Novel Inhibitors of Acetyl- and Butyrylcholinesterase Derived from the Alkaloids Dehydroevodiamine and Rutaecarpine. Eur. J. Med. Chem. 2005, 40, 305-313.
14. Decker, M.; Krauth, F.; Lehmann, J. Novel Tricyclic Quinazolinimines and Related Tetracyclic Nitrogen Bridgehead Compounds as Cholinesterase Inhibitors with Selectivity towards Butyrylcholinesterase. Bioorg. Med. Chem. 2006, 14, 1966-1977.
15. Saxena, A.; Redman, A. M. G.; Jiang, X.; Lockridge, O.; Doctor, B. P. Differences in Active Site Gorge Dimensions of Cholinesterases Revealed by Binding of Inhibitors to Human Butyrylcholinesterase. Biochemistry 1997, 36, 14642-14651.
16. Pang, Y. P.; Quiram, P.; Jelacic, T.; Hong, F.; Brimijoin, S. Highly Potent, Selective, and Low Cost Bis-tetrahydroaminacrine Inhibitors of Acetylcholinesterase. Steps toward Novel Drugs for Treating Alzheimer's Disease. J. Biol. Chem. 1996, 271, 23646-23649.
17. Petersen, S.; Tietze, E. Die Reaktion cyclischer Lactimäther mit Aminocarbonsäuren. (Reaction of Cyclic Iminium Ethers with Aminocarbonic Acids.) Liebigs Ann. Chem. 1959, 623, 166-176.
18. Jaén, J. C.; Gregor, V. E.; Lee, C.; Davies, R.; Emmerling, M. Acetylcholinesterase Inhibition by Fused Dihydroquinazoline Compounds. Bioorg. Med. Chem. Lett. 1996, 6, 737-742.
19. Brown, D. J.; Ienaga, K. Dimroth Rearrangement. XVIII. Synthesis and Rearrangement of 4-Iminoquinazolines and Related Systems. J. Chem. Soc., Perkin Trans. 1 1975, 21, 2182-2185.
20. Ellman, G. L.; Courtney, K. D.; Andres, V.; Featherstone, R. M. A New and Rapid Colorimetric Determination of Acetylcholinesterase Activity. Biochem. Pharmacol. 1961, 7, 88-95.